EXTENDED REPORT

¹ German Rheumatism Research Centre, Berlin, Germany
² Medizinische Hochschule, Hannover, Germany
³ Heinrich-Heine-Universitaet, Duesseldorf, Germany

Correspondence to:
A Zink
Deutsches Rheuma-Forschungszentrum Berlin, Forschungsbereich Epidemiologie, Schumannstr. 21/22, D 10117 Berlin, Germany; Zink{at}DRFZ.de

Objective: To estimate and compare the direct and indirect costs of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE), and to evaluate the effect of sex, disease duration and functional status on the various cost domains.

Methods: Data of outpatients, aged 18–65, with rheumatoid arthritis (n = 4351), ankylosing spondylitis (n = 827), PsA (n = 908) or SLE (n = 844), who were enrolled in the national database of the German collaborative arthritis centres in 2002, were analysed. Data on healthcare consumption, out-of-pocket expenses and productivity losses were derived from doctors and patients. For the calculation of indirect costs, the human capital approach (HCA) and the friction cost approach (FCA) were applied.

Results: Mean direct costs amounted to 4737 a year in rheumatoid arthritis, 3676 in ankylosing spondylitis, 3156 in PsA and 3191 in SLE. By using the HCA, total costs were calculated at 15 637 in rheumatoid arthritis, 13 513 in ankylosing spondylitis, 11 075 in PsA and 14 411 in SLE, whereas with the FCA the numbers were 7899, 7204, 5570 and 6518, respectively. Costs increased with disease duration and were strongly dependent on functional status. In patients with the highest disability (<50% of full function), the total costs on applying the HCA were 34 915 in rheumatoid arthritis, 29 647 in alkylosing spondylitis, 37 440 in PsA and 32 296 in SLE.

Conclusion: The costs of illness are high in all four diseases, with a strong effect of functional status on total costs. Indirect costs differ by the factor 3, based on whether the HCA or the FCA is used.

Abbreviations: FCA, friction cost approach; FFbH, Hannover Functional Status Questionnaire; HAQ, Health Assessment Questionnaire; HCA, human capital approach; PsA, psoriatic arthritis; SLE, systemic lupus erythematosus

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Olivieri, I., de Portu, S., Salvarani, C., Cauli, A., Lubrano, E., Spadaro, A., Cantini, F., Cutro, M. S., Mathieu, A., Matucci-Cerinic, M., Pappone, N., Punzi, L., Scarpa, R., Mantovani, L. G., for the PACE working group, (2008). The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology (Oxford) 47: 1664-1670 [Abstract] [Full Text]  
• Konnopka, A, Conrad, K, Baerwald, C, Konig, H-H (2008). Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. Ann Rheum Dis 67: 1399-1405 [Abstract] [Full Text]  
• Zhu, T. Y., Tam, L.-S., Lee, V. W.-Y., Hwang, W. W., Li, T. K., Lee, K. K., Li, E. K. (2008). Costs and quality of life of patients with ankylosing spondylitis in Hong Kong. Rheumatology (Oxford) 47: 1422-1425 [Abstract] [Full Text]  
• Clarke, A. E., Panopalis, P., Petri, M., Manzi, S., Isenberg, D. A., Gordon, C., Senecal, J.-L., Joseph, L., St Pierre, Y., Li, T. (2008). SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 47: 329-333 [Abstract] [Full Text]  
• Kobelt, G. (2007). Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 66: iii35-iii39 [Abstract] [Full Text]  
• Zijlstra, T. R., Braakman-Jansen, L. M. A., Taal, E., Rasker, J. J., van de Laar, M. A. F. J. (2007). Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology (Oxford) 46: 1454-1459 [Abstract] [Full Text]